• Latest Posts

GSK goes to phase II with German Antibody for Inflammatory Diseases

Two of the Biggest European Biotechs launch Antibody Program together

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?


This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

Meet the CEO of Europe’s Leading Microbiome Biotech

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials